JP Morgan Chase
DFTX

JP Morgan Chase’s Definium Therapeutics DFTX Stock Holding History

JP Morgan Chase’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,600
Closed -$33.8K – 7609
2024
Q1 		$33.8K Hold
3,600
– – ﹤0.01% 6076
2023
Q4 		$13.2K Buy
+3,600
New +$10.8K ﹤0.01% 6343

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase's DFTX Position: Q1 2026 in Review

JP Morgan Chase increased its Definium Therapeutics (DFTX) stake by 72% in Q1 2026, buying an estimated $1.88M and bringing the position to 264,545 shares worth $4.63M. The position accounts for ﹤0.01% of the portfolio, ranked #3383.

JP Morgan Chase first reported a position in DFTX in Q2 2021 and has held it in 20 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • JP Morgan Chase held 264,545 shares of Definium Therapeutics worth $4.63M as of Q1 2026.
  • JP Morgan Chase bought 110,823 Definium Therapeutics shares in Q1 2026, an estimated $1.88M.
  • Definium Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3383 holding.
  • JP Morgan Chase first reported a position in Definium Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.